InvestorsHub Logo
Post# of 252279
Next 10
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: biomaven0 post# 162581

Saturday, 06/15/2013 11:12:05 PM

Saturday, June 15, 2013 11:12:05 PM

Post# of 252279
True I didn't study the trial's inclusion/exclusion criteria but still surprising that with IC50 for parental ALK at 4-5 times lower than Criz, LDK yields similar RR. I assumed Medscape did some comparison before making this post-ASCO presentation.

http://img.medscape.com/images/805/623/805623_slides.ppt

I see LDK will go head to head with pemexetred both in Criz naive and Criz resistant in the PH3 trials. in PH3 Criz showed PFS of 7.7 mos. vs. 4.2 mos. PEM, and ORR was 66% vs. 29% PEM.

Just my opinion but I think LDK's PH3 results will be similar to Criz results, not show a 2nd gen improvement.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.